Page last updated: 2024-10-19

niacinamide and Sepsis

niacinamide has been researched along with Sepsis in 8 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.

Research Excerpts

ExcerptRelevanceReference
"Although both reached severe aplasia of the bone marrow without blastic infiltration, death occurred with neutropenic sepsis."2.52Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors. ( Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D, 2015)
" These results demonstrate that RJX-P and RJX-B are bioequivalent relative to their pharmacodynamic effects on tissue SOD and ascorbic acid levels."1.62Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX). ( Orhan, C; Ozercan, IH; Powell, J; Sahin, E; Sahin, K; Uckun, FM; Volk, M, 2021)
"Sepsis is a common clinical critical disease, which is one of the main causes of septic shock and multiple organ dysfunction syndrome (MODS)."1.56[Progress of nicotinamide in preventing infection and sepsis]. ( Chen, T; Cheng, L; Liang, H; Liu, K; Liu, Y, 2020)
"Sepsis-caused multiple organ failure remains the major cause of morbidity and mortality in intensive care units."1.48Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. ( Fan, GC; Hong, G; Lu, Z; Ni, R; Peng, T; Wang, G; Zhang, L; Zheng, D, 2018)
"Lethal endotoxemia was induced by intraperitoneal administration of LPS at a dose of 20 mg/kg."1.38Therapeutic benefits of the group B3 vitamin nicotinamide in mice with lethal endotoxemia and polymicrobial sepsis. ( Ge, P; Li, H; Li, L; Wan, J; Yuan, H; Zhang, L, 2012)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (50.00)24.3611
2020's4 (50.00)2.80

Authors

AuthorsStudies
Uckun, FM2
Saeed, M1
Awili, M1
Ozercan, IH2
Qazi, S1
Lee, C1
Shibli, A1
Skolnick, AW1
Prusmack, A1
Varon, J1
Barrera, CI1
Orhan, C2
Volk, M2
Sahin, K2
Brichacek, AL1
Benkovic, SA1
Chakraborty, S1
Nwafor, DC1
Wang, W1
Jun, S1
Dakhlallah, D1
Geldenhuys, WJ1
Pinkerton, AB1
Millán, JL1
Brown, CM1
Cheng, L1
Chen, T1
Liu, Y1
Liu, K1
Liang, H1
Suchard, MS1
Savulescu, DM1
Powell, J1
Sahin, E1
Hong, G1
Zheng, D1
Zhang, L2
Ni, R1
Wang, G1
Fan, GC1
Lu, Z1
Peng, T1
Yılmaz Karapınar, D1
Karadaş, N1
Önder Siviş, Z1
Balkan, C1
Kavaklı, K1
Aydınok, Y1
Yuan, H1
Wan, J1
Li, L1
Ge, P1
Li, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants[NCT03680105]Phase 176 participants (Actual)Interventional2018-08-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).

Number of participants with abnormal and clinically significant findings based on ECG. (NCT03680105)
Timeframe: Up to Day 2 for Part 1 and Up to Day 8 for Part 2

InterventionParticipants (Count of Participants)
Part 1; Placebo0
Part 1; Cohort 1; RJX0
Part 1; Cohort 2; RJX0
Part 1; Cohort 3; RJX0
Part 1; Cohort 4; RJX0
Part 1; Cohort 5; RJX0
Part 1; Cohort 6; RJX0
Part 2; Placebo0
Part 2; Cohort 1; RJX0
Part 2; Cohort 2; RJX0
Part 2; Cohort 3; RJX0

Safety and Tolerability of RJX as Assessed by Neurological Examinations.

Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments. (NCT03680105)
Timeframe: Up to Day 5 for Part 1 and Up to Day 12 for Part 2

InterventionParticipants (Count of Participants)
Part 1; Placebo0
Part 1; Cohort 1; RJX0
Part 1; Cohort 2; RJX0
Part 1; Cohort 3; RJX0
Part 1; Cohort 4; RJX0
Part 1; Cohort 5; RJX0
Part 1; Cohort 6; RJX0
Part 2; Placebo0
Part 2; Cohort 1; RJX0
Part 2; Cohort 2; RJX1
Part 2; Cohort 3; RJX0

Treatment-related Adverse Events (TEAE) Reporting of RJX

Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03 (NCT03680105)
Timeframe: Up to Day 5 for Part 1 and Up to Day 12 for Part 2

InterventionParticipants (Count of Participants)
Mild TEAE72191553Mild TEAE72191554Mild TEAE72191555Mild TEAE72191556Mild TEAE72191557Mild TEAE72191558Mild TEAE72191559Mild TEAE72191560Mild TEAE72191562Mild TEAE72191563Mild TEAE72191561Moderate TEAE72191553Moderate TEAE72191554Moderate TEAE72191555Moderate TEAE72191556Moderate TEAE72191557Moderate TEAE72191558Moderate TEAE72191559Moderate TEAE72191560Moderate TEAE72191561Moderate TEAE72191562Moderate TEAE72191563Severe TEAE72191553Severe TEAE72191554Severe TEAE72191555Severe TEAE72191556Severe TEAE72191557Severe TEAE72191558Severe TEAE72191559Severe TEAE72191560Severe TEAE72191561Severe TEAE72191562Severe TEAE72191563Related TEAE72191553Related TEAE72191554Related TEAE72191555Related TEAE72191556Related TEAE72191558Related TEAE72191559Related TEAE72191560Related TEAE72191561Related TEAE72191562Related TEAE72191563Related TEAE72191557
Without TEAEWith TEAE
Part 1; Placebo2
Part 1; Cohort 1; RJX1
Part 1; Cohort 2; RJX2
Part 1; Cohort 3; RJX0
Part 1; Cohort 4; RJX2
Part 1; Cohort 5; RJX2
Part 1; Cohort 6; RJX0
Part 2; Placebo1
Part 2; Cohort 1; RJX1
Part 2; Cohort 2; RJX3
Part 2; Cohort 3; RJX2
Part 1; Placebo11
Part 1; Cohort 1; RJX5
Part 1; Cohort 2; RJX4
Part 1; Cohort 3; RJX6
Part 1; Cohort 5; RJX4
Part 1; Cohort 6; RJX9
Part 2; Placebo5
Part 2; Cohort 1; RJX5
Part 2; Cohort 3; RJX4
Part 1; Placebo0
Part 1; Cohort 1; RJX0
Part 1; Cohort 4; RJX1
Part 1; Cohort 5; RJX1
Part 2; Cohort 1; RJX0
Part 2; Cohort 2; RJX0
Part 2; Cohort 3; RJX1
Part 1; Placebo13
Part 1; Cohort 1; RJX6
Part 1; Cohort 2; RJX6
Part 1; Cohort 4; RJX5
Part 1; Cohort 5; RJX5
Part 2; Cohort 1; RJX6
Part 2; Cohort 2; RJX6
Part 2; Cohort 3; RJX5
Part 1; Cohort 2; RJX0
Part 1; Cohort 4; RJX0
Part 1; Cohort 5; RJX0
Part 2; Placebo0
Part 1; Cohort 4; RJX6
Part 1; Cohort 5; RJX6
Part 2; Placebo6
Part 1; Cohort 2; RJX1
Part 2; Cohort 2; RJX2
Part 2; Cohort 3; RJX0
Part 1; Cohort 2; RJX5
Part 1; Cohort 4; RJX4
Part 2; Cohort 2; RJX4
Part 2; Cohort 3; RJX6

Reviews

2 reviews available for niacinamide and Sepsis

ArticleYear
Nicotinamide pathways as the root cause of sepsis - an evolutionary perspective on macrophage energetic shifts.
    The FEBS journal, 2022, Volume: 289, Issue:4

    Topics: Animals; Biological Evolution; COVID-19; Energy Metabolism; Humans; Macrophages; Niacinamide; Sepsis

2022
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3

    Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols;

2015

Other Studies

6 other studies available for niacinamide and Sepsis

ArticleYear
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis.
    Future microbiology, 2022, Volume: 17

    Topics: Animals; Anti-Inflammatory Agents; Ascorbic Acid; COVID-19 Drug Treatment; Dexamethasone; Disease Mo

2022
Systemic inhibition of tissue-nonspecific alkaline phosphatase alters the brain-immune axis in experimental sepsis.
    Scientific reports, 2019, 12-11, Volume: 9, Issue:1

    Topics: Alkaline Phosphatase; Animals; Astrocytes; Blood-Brain Barrier; Brain; Endothelial Cells; Female; Im

2019
[Progress of nicotinamide in preventing infection and sepsis].
    Zhonghua wei zhong bing ji jiu yi xue, 2020, Volume: 32, Issue:7

    Topics: Humans; Multiple Organ Failure; Niacinamide; Poly(ADP-ribose) Polymerases; Sepsis; Shock, Septic; Vi

2020
Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 141

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Dose-Response Relationship, Drug; Dr

2021
Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis.
    Free radical biology & medicine, 2018, 08-01, Volume: 123

    Topics: Animals; Apoptosis; Disease Models, Animal; HMGB1 Protein; Lipopolysaccharides; Macrophages; Male; M

2018
Therapeutic benefits of the group B3 vitamin nicotinamide in mice with lethal endotoxemia and polymicrobial sepsis.
    Pharmacological research, 2012, Volume: 65, Issue:3

    Topics: Animals; Endotoxemia; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred BALB C; Niacinamide; Seps

2012